Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
about
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid LeukemiaThe role of reduced intracellular concentrations of active drugs in the lack of response to anticancer chemotherapyRole of breast cancer resistance protein (BCRP/ABCG2) in cancer drug resistanceRole of the plasma membrane transporter of organic cations OCT1 and its genetic variants in modern liver pharmacologyResistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment optionsFinasteride concentrations and prostate cancer risk: results from the Prostate Cancer Prevention TrialGenotypes of SLC22A4 and SLC22A5 regulatory loci are predictive of the response of chronic myeloid leukemia patients to imatinib treatment.PharmGKB summary: very important pharmacogene information for SLC22A1ABCB1 regulation through LRPPRC is influenced by the methylation status of the GC -100 box in its promoter.Genetic variants in transcription factors are associated with the pharmacokinetics and pharmacodynamics of metformin.Wnt/β-catenin pathway regulates ABCB1 transcription in chronic myeloid leukemia.The pharmacogenetics of imanitib.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Interaction of innovative small molecule drugs used for cancer therapy with drug transporters.Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentContribution of tumoral and host solute carriers to clinical drug response.Whole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia.Association between imatinib transporters and metabolizing enzymes genotype and response in newly diagnosed chronic myeloid leukemia patients receiving imatinib therapy.The Impacts of SLC22A1 rs594709 and SLC47A1 rs2289669 Polymorphisms on Metformin Therapeutic Efficacy in Chinese Type 2 Diabetes Patients.ABCB1 haplotypes do not influence transport or efficacy of tyrosine kinase inhibitors in vitroHigh imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patientsGenetic polymorphisms of metabolic enzymes and the pharmacokinetics of indapamide in Taiwanese subjectsHepatic OATP and OCT uptake transporters: their role for drug-drug interactions and pharmacogenetic aspects.Techniques for risk stratification of newly diagnosed patients with chronic myeloid leukemia.Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Genetic determinants of anticancer drug activity: towards a global approach to personalized cancer medicine.Clinical pharmacology of axitinib.Clinical relevance of pharmacogenetics in gastrointestinal stromal tumor treatment in the era of personalized therapy.Polymorphisms of the drug transporters ABCB1, ABCG2, ABCC2 and ABCC3 and their impact on drug bioavailability and clinical relevance.ABCB1 polymorphisms predict imatinib response in chronic myeloid leukemia patients: a systematic review and meta-analysis.Physicochemical properties of novel protein kinase inhibitors in relation to their substrate specificity for drug transporters.Polymorphisms of ERCC1 genotype associated with response to imatinib therapy in chronic phase chronic myeloid leukemia.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.Chronic Myeloid Leukemia in the Era of Tyrosine Kinase Inhibitors: An Evolving Paradigm of Molecularly Targeted Therapy.ABCB1 haplotypes but not individual SNPs predict for optimal response/failure in Egyptian patients with chronic-phase chronic myeloid leukemia receiving imatinib mesylate.Impact of Transporter Polymorphisms on Drug Development: Is It Clinically Significant?Do SLCO1B3 (T334G) and CYP3A5*3 polymorphisms affect response in Egyptian chronic myeloid leukemia patients receiving imatinib therapy?
P2860
Q26781539-4FFC73F1-9272-48B2-BF51-36512B09E097Q26830005-C1DE76DB-5007-4AEF-B23D-7790442F6BE0Q26865927-3DD27DC3-7426-47A0-896E-C25EAB30E7A9Q27026858-DB37B8AA-C1BE-46C5-9825-3BA0291E0D42Q27028181-0D3C164F-32E1-4620-B70F-C507F1EACDF5Q28547130-7062EC9D-1E17-45F3-8524-A177142EEB91Q33577088-562BF485-B463-4CD2-BDA8-BB1962B8B2D8Q33671763-DDC40E78-7190-4637-A740-EF68E2B84284Q34183433-2E018EB7-E447-4906-82B1-DAB6F184E1C8Q34224429-4458C1CE-2377-450F-87CA-5945DA661727Q34348134-F16238A9-C90A-4EFD-B3DA-26A5934CF163Q34469295-84E25FE5-B373-4A43-B145-F1E474D7A2DDQ34525644-7D2626F8-8D61-42AE-9DE0-904D05FEE6C8Q35708124-910523DC-BB88-4D3A-8538-6B7B27B9224DQ35922779-97CC190B-D577-4F19-81B4-E12092EE303AQ35946876-9B35F24F-758D-4C28-B520-151C7A8EC080Q36035404-AF0FA521-DE88-4539-9BE0-1BCC1A667063Q36546628-7DFAB66D-9D9A-4FE7-8F15-36263422A0E5Q36579071-7E256B23-9767-4D9A-8728-976EF7CABE80Q36610479-B60380AF-CF72-438A-9B74-D79F8A18E342Q37140624-EEDA97C2-A469-4753-A6DA-7E138BC2AD03Q37381574-5CE5B7C4-579B-46F1-9D86-FCF7F968C227Q37601055-8368BC36-9935-47B3-878C-FB620D4792F4Q37680968-7C987141-7332-4E0B-8A62-8B03E7CCD7C4Q37836922-221E6C32-3393-4249-970B-668973B68507Q37859303-EC8106F1-15C2-47D9-8D0F-C16CED6228C1Q37899883-28DE32D7-C439-445D-8628-72A8849E2105Q38107175-6A7024A8-E654-44DF-89EE-A29D6593CA79Q38112821-E3F0C8A4-C5B1-41B4-BF8E-B3CB392DB842Q38243832-0AA52038-807B-4104-8639-FFCF741C107FQ38253243-A4B6E704-6940-49AF-A0B8-05D8F9054515Q38336723-1FEF9994-101E-4187-A2E5-922B10C8565FQ38460343-79CEC2FC-D88D-4C3C-A756-95DFDB688790Q38540022-DE5C988E-3A0B-48C7-8F1E-599C08093C2FQ38622785-AED2F4B1-6B39-4257-87FC-CE7AAC7934ADQ38826494-186EF068-CD11-4DCA-A169-A8BE546312A5Q38843265-F052B8D1-5050-4B95-970B-9AC750DB5C4CQ38868934-391C883A-D073-45D9-A737-034FE086381CQ38888369-F1C5A461-8689-4802-ACB8-2DF502808C42Q38899401-63869947-3566-4594-A230-45B18D5C3E6A
P2860
Clinical relevance of a pharmacogenetic approach using multiple candidate genes to predict response and resistance to imatinib therapy in chronic myeloid leukemia.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@en
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@nl
type
label
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@en
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@nl
prefLabel
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@en
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@nl
P2093
P1476
Clinical relevance of a pharma ...... y in chronic myeloid leukemia.
@en
P2093
Dong Hwan Dennis Kim
Hans A Messner
Jeffrey H Lipton
Katherine Siminovitch
Lakshmi Sriharsha
Xiangdong Liu
P304
P356
10.1158/1078-0432.CCR-09-0145
P407
P577
2009-07-07T00:00:00Z